.jpeg){kind=logo}
JOSEPH MMWAIf it's health, it's here
The study is led by the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, a joint Uganda and UK research unit, working with Oxford, which developed the vaccine.
Volunteers in Uganda have started receiving an experimental vaccine built to fight Bundibugyo Ebola, the strain behind an outbreak in neighbouring Democratic Republic of Congo that had killed more than 4,200 people by early October.
No vaccine or specific treatment is licensed for it.
The tests are at an early stage and cannot yet show whether the vaccine protects anyone, but this is the step that has to come first.
The first participants were vaccinated on 6 October 2026 in Masaka City, in southwestern Uganda, according to a University of Oxford release published on 7 October.
The study is led by the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, a joint Uganda and UK research unit, working with Oxford, which developed the vaccine.
Premium article
A membership unlocks this story and every other premium article, with no separate purchase per story.
Become a member